Journal of Clinical Immunology

, Volume 31, Issue 4, pp 690–698

Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining

  • Anita Schwandt
  • Jorge A. Garcia
  • Paul Elson
  • Jeanie Wyckhouse
  • James H. Finke
  • Joanna Ireland
  • Pierre Triozzi
  • Ming Zhou
  • Robert Dreicer
  • Brian I. Rini
Article

DOI: 10.1007/s10875-011-9530-x

Cite this article as:
Schwandt, A., Garcia, J.A., Elson, P. et al. J Clin Immunol (2011) 31: 690. doi:10.1007/s10875-011-9530-x

Abstract

Introduction

Cycloxygenase-2 (COX-2) is an enzyme involved in prostaglandin E2 (PGE2) synthesis associated with higher renal cell carcinoma stage. COX-2 inhibition enhances interferon (IFN-α) anti-tumor immune effects in pre-clinical models. A phase II trial of celecoxib and IFN-α in a targeted population of metastatic renal cell carcinoma patients with maximal COX-2 expression was conducted.

Methods

Cytokine-naive metastatic renal cell carcinoma patients with tumors expressing ≥10% maximal COX-2 staining by immunohistochemistry received IFN-α 5 million units daily and celecoxib 400 mg orally twice daily in an open-label, single-arm phase II trial.

Results

There were 3 partial responses among 17 patients (objective response rate 18%; 95% confidence interval, 4–43%). Time to progression was 5.6 months. Increased tumor staining 3+ for COX-2 was associated with increased baseline peripheral blood PGE2 levels, and these patients demonstrated less PGE2 decrease with therapy. Patients with more 3+ COX-2 staining had significantly more CD3+ (p = 0.004) and CD4+ (p = 0.002) IFN-γ T cells at baseline and a significantly greater decrease in these cells with therapy.

Discussion

Celecoxib plus IFN-α in renal cell carcinoma (RCC) patients with maximally staining COX-2 tumors does not significantly enhance overall response rates over IFN monotherapy.

Conclusion

COX-2-expressing RCC demonstrates inherent immunosuppression. COX-2 inhibition with IFN results in minimal immunomodulation and no augmented clinical activity in RCC.

Keywords

Interferon-α celecoxib renal cell carcinoma immunotherapy T-regulatory cells 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Anita Schwandt
    • 1
  • Jorge A. Garcia
    • 1
  • Paul Elson
    • 2
  • Jeanie Wyckhouse
    • 1
  • James H. Finke
    • 3
  • Joanna Ireland
    • 3
  • Pierre Triozzi
    • 1
  • Ming Zhou
    • 4
  • Robert Dreicer
    • 1
  • Brian I. Rini
    • 1
  1. 1.Department of Solid Tumor OncologyCleveland Clinic Taussig Cancer InstituteClevelandUSA
  2. 2.Department of Quantitative Health SciencesCleveland ClinicClevelandUSA
  3. 3.Department of ImmunologyLerner Research Institute, Cleveland ClinicClevelandUSA
  4. 4.Department of PathologyCleveland ClinicClevelandUSA

Personalised recommendations